1 3 5 1 a r t I C l e S Axons are extremely long structures with high metabolic demands due to constant ion fluxes, transport of cargoes and maintenance of their large cell-membrane surface area. It is increasingly realized that axonal integrity depends not only on neuron-derived provisions but also on support from SCs and oligodendrocytes 1,2 , the enwrapping glia of the peripheral and central nervous systems (PNS and CNS), respectively. The mechanisms for this non-cell-autonomous support function remain obscure, but emerging evidence indicates that it is distinct from the glial role of insulating axons with myelin 1-3 . Metabolic substrates produced in oligodendrocytes seem to be essential for CNS axonal support 4,5 , as inhibiting transport of glycolysisderived carbohydrates (for example, pyruvate and lactate) from glia to axons results in axonal damage 5 . In accord, mitochondrial respiration in oligodendrocytes is reported to be dispensable for axon integrity, as mitochondrial disruption does not cause axonal degeneration as long as glycolytic pathways remain intact 4 .
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It remains unknown whether metabolic pathways in SCs may be important for axon maintenance in the PNS. Using models of SC mitochondrial dysfunction, we recently implicated abnormalities in the integrated stress response, as well as lipotoxic mechanisms, in peripheral nerve demyelination with axon loss 6 . A possible impact of aberrant SC metabolism on axon integrity was also observed in another SC mitochondrial disruption model characterized by abundant nerve demyelination and neuroinflammation 4 .
While these studies attempted to shed light on glial roles in providing axon support, the metabolic control systems in enwrapping glia remain unexplored. Moreover, whether metabolic imbalances that occur in disease similarly affect axonal integrity is particularly significant given the broad association between aberrant metabolism, aging and diverse neurodegenerative conditions with axonal damage. Notably, diabetic neuropathy occurs in association with abnormal glucose and lipid metabolism. Many of the symptoms in this neuropathy result from sensory axon degeneration 7 , and it has been proposed that metabolic changes in SCs are involved 8, 9 . To examine the glia-axon relationship from this perspective, we sought to identify metabolic regulatory pathways in SCs that are essential for axon maintenance.
The serine/threonine kinase LKB1 (also known as Stk11) and its prime downstream target, AMPK, maintain cellular energy homeostasis by regulating key pathways of lipid, carbohydrate and protein metabolism 10, 11 . LKB1 also modulates metabolism independently of AMPK by less well-characterized mechanisms, most notably via several AMPK-related kinases 12, 13 . In addition to alterations of LKB1-AMPK signaling in metabolic disease and obesity, deregulation of both kinases has been implicated in neurodegeneration, including diabetic neuropathy, aging, cancer and other conditions 10, 14, 15 . Maintenance of energy homeostasis during cellular stress involves activation of AMPK by LKB1 or alternative upstream kinases to induce catabolism and suppress anabolic processes, to a large degree through inhibition of mTOR 16, 17 .
To determine whether LKB1-AMPK signaling contributes to glial support of axon integrity, we ablated LKB1 and several downstream targets, including the AMPK complex and mTOR, in SCs in vivo. In support of a crucial role for glial metabolic homeostasis in axon maintenance, we found that SC-specific LKB1 mutants displayed a pattern a r t I C l e S of axonal degeneration that is reminiscent of some aspects of diabetic neuropathy. Notably, similar SC-specific inactivation of AMPK or the downstream mTOR kinase, as well as further metabolic manipulation in SCs, did not result in axon degeneration. Overall, our study identifies LKB1 as an important metabolic regulator of SC-derived axonal support and provides a molecular basis for new glia-centric therapeutic avenues for neuropathies.
RESULTS

Effects of SC-specific LKB1 ablation on nerve development
To study the effects of early LKB1 inactivation specifically in SCs, we bred Lkb1 fl/fl mice to transgenic mice that express Cre recombinase (starting from embryonic day (E) ~14.5) under control of the P0 (also known as Mpz) promoter. We observed efficient recombination of the floxed Lkb1 (Stk11) allele in nerve genomic DNA from mutant Lkb1 fl/fl : P0-cre (henceforth termed LKB1-SCKO) mice and clear reductions in Lkb1 transcript (0.6 ± 0.04-fold lower in quantitative real-time (qRT)-PCR quantification normalized to Gapdh expression; mean ± s.e.m., n = 3 mice per genotype; P < 0.001) and protein levels in postnatal day (P) 30 sciatic nerves (Fig. 1a,b and Supplementary Fig. 1a,b) . LKB1-SCKO mutant mice were born at the predicted Mendelian frequency and were normal in weight and size until ~4 months of age ( Supplementary Fig. 1c ). At older ages, these mutants showed weight decreases (on average about 21%). Nerve conduction velocities in mutant animals at P30 were reduced from 32.14 ± 2.36 m/s (n = 7) to 20.31 ± 1.48 m/s (n = 8) (P < 0.001) without a decrease in compound muscle action potential (CMAP) amplitudes (Supplementary Fig. 2a ). This correlated with an early, transient delay in radial sorting and formation of compact myelin at P3-21 that had largely reversed by P30, although g-ratio (axon diameter/myelinated fiber diameter) remained elevated ( Fig. 1c and Supplementary Fig. 2b,c) . SC differentiation in LKB1-SCKO nerves was impaired as observed by increased numbers of Oct6-and Sox2-positive cells in P21 mutant nerves (Fig. 1d) . This was accompanied by significantly reduced levels of the active fragment of axonal neuregulin 1 (Fig. 1e and Supplementary Fig. 2d ). In contrast, and likely accounting for the compensatory effects in myelination, we found elevated expression of ERBB2 and ERBB3 receptors by western blotting of P30 mutant nerve lysates (statistical significance for ERBB3 not reached) ( Fig. 1e and Supplementary Fig. 2d ). Additionally, mutant SCs strongly expressing Egr2 were more numerous than in control nerves at P21 (Fig. 1d) . Despite these alterations in nerve development, primary SC cultures established from P30 LKB1-SCKO sciatic nerves were morphologically indistinguishable from control cultures (Fig. 1f) , and we did not observe differences in SC proliferation and cell death (data not shown).
LKB1 deficiency can lead to defects in cell polarity 18, 19 . However, analysis of longitudinal SC polarization at P60 did not reveal any overt abnormalities in LKB1-deficient nerves (Supplementary Fig. 3 ). This suggests that, similarly to that in other cell types [20] [21] [22] , ablation of LKB1 in SCs does not cause major polarity defects. Notably, LKB1-SCKO nerves contained normal numbers of axons at P60 (see Fig. 2 below).
LKB1 deletion in SCs leads to metabolic deregulation
Conditional deletion of LKB1 can be associated with aberrant metabolism and energy depletion [23] [24] [25] . To examine whether this is also the case for SCs, we performed untargeted metabolomics analysis 26 on sciatic C o n t r o l M u t a n t npg a r t I C l e S nerve metabolite extracts from P60 mice. The LKB1-SCKO samples differed markedly from control preparations, with differential regulation of more than 1,500 metabolic features as defined by unique coordinate pairs of mass-to-charge ratios (m/z) and chromatographic retention times ( Supplementary Fig. 4) . Using model compound databases, we tentatively identified 733 dysregulated metabolites (Supplementary Table 1) . Lipids were over-represented relative to amino acids/peptides and carbohydrates; this included several SC lipid classes such as phospholipids (for example, phosphatidylcholine species) and glycolipids (for example, sulfatides and cerebrosides) 27 . Moreover, we observed changes in concentrations of amino acids and small peptides, as well as elevated lactate in LKB1-SCKO preparations (lactic acid; Kyoto Encyclopedia of Genes and Genomes (KEGG) C01432; 2.66-fold upregulated; P = 0.000208). We next measured AMP and ATP concentrations in sciatic nerve preparations. This demonstrated relatively constant AMP/ATP ratios in control nerves from P30 onwards. In contrast, gradual ATP depletion in LKB1-SCKO nerves resulted in progressively increasing AMP/ATP ratios (Fig. 2a) . This energy deprivation was accompanied by an age-dependent decrease in NAD + /NADH ratios, driven by significant elevations in NADH levels while NAD + concentrations remained constant (Fig. 2b,c) . SC numbers in LKB1-SCKO nerves, however, were indistinguishable from those in control nerves, with no evidence of increased SC apoptosis (Supplementary Fig. 5a-d) . These studies indicate that SCs from LKB1-SCKO mutant nerves with metabolic dysregulation are energetically deficient, possibly secondarily to defects in oxidative phosphorylation as observed in other LKB1-deficient cell types [23] [24] [25] .
LKB1-SCKO mutants develop progressive axonopathy
We next studied the consequences of dysregulated SC metabolism for nerve integrity. A subset of LKB1-SCKO mutants (~10%) began to develop substantial neurological abnormalities (for example, unsteady gait and hindlimb clasping) indicative of peripheral neuropathy by P90. The abnormalities progressively worsened with age, such that all 12-month-old mutants showed signs of neuropathy (Supplementary Fig. 5e ). Several 18-month-old mutants displayed severe ambulatory impairment but did not have overt muscle paralysis (Supplementary Video 1) .
Degeneration of myelinated and unmyelinated axons became initially apparent in P90 LKB1-SCKO sciatic and femoral nerves (Fig. 2d,e and data not shown). The fiber degeneration gradually progressed (Fig. 2j-m,p) and was especially prominent for unmyelinated axons (Fig. 2h,i,n,o,q) . Nerves from many 12-to 18-month-old mutant mice were almost completely devoid of unmyelinated axons (Fig. 2j-o) . We further examined the degeneration using LKB1-SCKO mice with neuronal yellow fluorescent protein (YFP) expression, which showed axonal fragmentation and swelling that was accentuated in aged mice (Fig. 2f,g and Supplementary Fig. 5f ). The axon loss was accompanied by reduced nerve size with a higher density of SCs (Supplementary Fig. 5g,h ). Fig. 6a,b) . Whereas age-matched vehicle-treated Lkb1 fl/fl :Plp-cre ERT and tamoxifen-treated Lkb1 fl/fl control mice exhibited no abnormalities, 12-month-old LKB1-iSCKO mutants showed abnormal gait, ambulatory deficits and ataxia (Supplementary Videos 2 and 3 and Supplementary Fig. 6c ). Morphological analysis of sciatic nerves from these mutants demonstrated many collapsed myelinated fibers ( Fig. 3a-d) , marked disintegration of unmyelinated axons (Fig. 3e,f ) and significant reductions in overall axon numbers (Fig. 3g,h) . Notably, these degenerative events were not preceded or accompanied by structural changes in the myelin of intact axons ( Supplementary Fig. 6d-f) . Indeed, nerve conduction velocities were normal in LKB1-iSCKO mutants 3 and 10 months after tamoxifen administration (Supplementary Fig. 6g ). These results demonstrate that LKB1 function in SCs is required for axon maintenance in adulthood after nerve development is completed, whereas its function is dispensable for SC myelin maintenance. In conclusion, LKB1 in SCs is essential for the preservation of both unmyelinated and myelinated axons independently of myelination.
Preferential loss of sensory axons in LKB1-SCKO mutants Although we observed substantial axon loss in adult LKB1-SCKO mutants, there was a distinct absence of overt motor symptoms. We performed assays for motor function and found only subtle deficits in aged LKB1-SCKO mice ( Supplementary Fig. 7a,b ). There were deficits in the rotarod test, but only in mutant mice older than 12 months of age (Supplementary Fig. 7c ). In the absence of reduced muscle strength, we surmised that these abnormalities could be due to defects in coordination or tactile sensory defects, or both. However, pole climb and turn tests, which measure coordination, were also normal in aged mutants (Supplementary Fig. 7d) . Consistent with the relative preservation of the motor system, we observed no overt macroscopic or microscopic abnormalities in muscles in 12-and 16-month-old mutants (Supplementary Fig. 7e,f) , in sharp contrast to what is seen in other metabolic neuropathy models 4,28 . Moreover, there were no electrophysiological signs of muscle denervation, significant changes in proximal and distal motor axon numbers, or axon terminal abnormalities at neuromuscular junctions of peripheral muscles in aged LKB1-SCKO mice (Fig. 4a,d, Supplementary Fig. 8a-d and data not shown). However, in quadriceps nerves (predominantly motor) of 18-month-old mutants, we did observe fewer myelinated axons, indicating that motor axons are not completely resistant to the changes elicited by LKB1 loss (Supplementary Fig. 8e) .
In contrast to the relative sparing of the motor system, the deterioration of unmyelinated fibers as noted by the progressive degeneration of Remak bundles was already accompanied by multiple sensory deficits in young animals. First, we found dramatic reductions of intraepidermal sensory terminals (C-fibers) in hind paws from LKB1-SCKO mice (Fig. 4b) . Loss of these skin nociceptor afferents results in defects in temperature sensitivity. In accord, hot-plate and Hargreaves tests revealed progressively longer reaction latencies, indicating reduced sensitivity to noxious heat stimuli in these mutants ( Fig. 4c and Supplementary Fig. 9a ). These deficits correlated well temporally with the degeneration of Remak bundles in LKB1-SCKO nerves (Fig.  2q) . We also observed abnormalities in the acetone and cold-plate tests (unmyelinated and thinly myelinated Aδ fibers), and smaller changes in von Frey mechanical sensitivity testing (myelinated Aβ fibers) (Supplementary Fig. 9b ,c and data not shown). To correlate these behavioral findings with structural data, we analyzed peripheral nerves containing predominantly sensory axons and spinal cord dorsal roots. Indeed, quantification of myelinated fibers in saphenous and sural nerves as well as L3 dorsal roots demonstrated significantly decreased axon numbers in 12-month-old or older mutants, but not in those at P45 (Fig. 4e, Supplementary Fig. 9d ,e and data not shown). This axon degeneration was not secondary to neuronal death, as overall numbers of L3 dorsal root ganglion neurons that project to these sensory nerves were indistinguishable between the groups (Supplementary Fig. 9f ). Taken together, these results prompted us to hypothesize that loss of LKB1 activity in SCs induces preferential destabilization of small-diameter fibers. We thus performed quantitative fiber morphometry in young and aged mice. Whereas we did not detect distribution differences in P90 mice (Supplementary Fig. 9g ), npg a r t I C l e S this analysis revealed that the percentage of small axons of 1-2 µm diameter was significantly reduced in 8-month-old LKB1-SCKO nerves (P = 0.003; Fig. 4f ). In sum, these results provide strong evidence that the axonopathy in LKB1-SCKO nerves primarily affects smalldiameter fibers, including the unmyelinated axons organized into Remak bundles as well as myelinated sensory axons.
Axon loss is not due to demyelination and inflammation Nerve demyelination and neuroinflammation as mechanisms for axon damage 1,3 were not apparent in LKB1-SCKO nerves-in accord with the data from LKB1-iSCKO mutants, in which axon degeneration occurred independently of changes in myelination. First, we did not observed histological signs of chronic demyelination (for example, onion bulb formation) in mutant nerves. Second, serial g-ratio measurements showed a gradual increase in myelin thickness in LKB1-SCKO nerves over time, rather than a progressive myelin thinning (Fig. 5a,b and Supplementary Fig. 10a ). Third, levels of main structural myelin proteins suggested conserved or even slightly improved myelin integrity in older mice (Fig. 5c) . Fourth, we did not detect overt macrophage and T-lymphocyte invasion in peripheral nerves by electron microscopic inspection, and we detected no significant increases in Iba1, CD68 or CD3 immunolabeling in 12-month-old LKB1-SCKO mice (P = 0.202, P = 0.745 and P = 0.553, respectively; Supplementary Fig. 10b-d) . Finally, there was no temporal dispersion in individual CMAP traces ( Fig. 5d ) or deterioration in nerve conduction velocity throughout the neuropathy (Fig. 5e) , findings that are inconsistent with progressive demyelination. The mouse vagus nerve is composed predominantly of unmyelinated axons, which showed dramatic degeneration in aged LKB1-SCKO mutants (Fig. 5f ). This indicates that unmyelinated vagal axons degenerate as a consequence of the metabolic perturbation in the LKB1 mutant non-myelinating SCs, and degeneration is not caused by demyelination.
More evidence that axon degeneration is not associated with demyelination in LKB1-SCKO nerves came from examination of longitudinal polarization of mutant SCs from aged mice. SC polarization defects occur in demyelinating neuropathies including abnormalities in the morphology of nodal and internodal areas of non-compact myelin (for example, ref. 6). Imaging of teased fiber preparations from aged LKB1-SCKO mutants expressing enhanced green fluorescent protein (EGFP) in SCs demonstrated that the overall configuration of the cytoplasmic network and SC polarity at internodes and nodes was normal (for example, normal arrangement of Schmidt-Lanterman incisures and Cajal bands) ( Fig. 5g) and was similar to the normal SC polarity observed in younger mutant mice before the onset of axon degeneration.
To gain more mechanistic insight into why these mutant SCs cannot provide adequate axonal support, we performed microarray analysis using nerve mRNA from P60 mice, an age immediately before the initiation of axonal loss (Supplementary Table 2 ). Transcripts of major regulators of PNS myelination (for example, Nrg-1, ErbB2/3, Egr2), as well as those encoding structural myelin proteins and key nerve inflammatory markers (for example, CSF-1, MCP-1), were normal in LKB1-SCKO nerves. Some notable exceptions included the downregulation of Lgi1 (leucine-rich, glioma inactivated 1) and the upregulation of chemokine ligand 14 (Cxcl14) and interleukin 10 receptor-α (Il1ra). Curiously, but as is compatible with reported LKB1 deletion phenotypes 29 , transcripts involved in melanin biosynthesis (for example, premelanosome protein Pme1, tyrosinase-related protein 1) were strongly upregulated in LKB1-depleted nerves. Moreover, we found aberrant regulation of transcripts implicated in lipid metabolism (for example, downregulation of squalene epoxidase, upregulation of acyl-CoA thioesterase). Notably, the profiling revealed induction of many genes encoding proteins collectively characteristic of dedifferentiated SCs and of the SC response to axon injury 30 (namely, Pou3f1 (also known as Oct6), Gdnf, Sox4, Shh, tenascin C (Tnc), cyclin D1 (Ccnd1), Mki67 (Ki67), Cd44, coronin (Coro2b), integrin-α3 (Itga3), receptor-type protein tyrosine phosphatase T (Ptprt), TNFR superfamily member 12a (Tnfrsf12a) and Tfap2a (also known as Tcfap2a)), as well as injury-associated nerve tissue remodeling 30 (namely, Mmp17, Ptprt, Cela1 (also known as Ela1), Klk10, Hapln2 and Klk8). In accordance, LKB1-deficient SCs Fig. 11 ). Thus, before the actual onset of axon loss, the LKB1-deficient SCs display a number of transcriptional changes reminiscent of the expression pattern associated with the SC axon injury response. It should be noted that some of the observed changes could also reflect delayed SC development in LKB1-SCKO nerves (see above).
LKB1 effects are independent of abolished AMPK and mTORC1
The axon degeneration in LKB1-SCKO mutants could result from abolished AMPK activation in SCs as a result of LKB1 loss, as LKB1 is often described as the main upstream kinase of AMPK 11 . The elimination of AMPK activity, in turn, leads to augmented mTOR complex 1 (mTORC1) activity, largely via reduced phosphorylation of tuberous sclerosis complex 2 (TSC2), the main inhibitor of mTORC1, and induction of Raptor, a critical component of mTORC1 complex 16, 17, 32 . Rapamycin, a drug that inhibits primarily mTORC1 signaling, can reverse some of the pathology observed following LKB1 ablation in other systems 10, 19, 21, 33, 34 . Given these observations, along with the apparent role of glial mTOR signaling in regulation of peripheral myelination 35 , we assessed the impact of pharmacological mTORC1 inhibition on the LKB1-SCKO axon phenotype. First, to validate our rapamycin treatment regime, we used SC-specific phosphatase and tensin homolog (PTEN) knockout mice (Pten fl/fl :P0-cre; PTEN-SCKO). These mutants displayed dysregulated mTORC1 signaling through Akt kinase (also known as protein kinase B) overactivation, leading to exuberant myelin growth and subsequent PNS axon degeneration (Fig. 6a) , similar to that in recently reported results from Pten fl/fl :Cnp-cre mutants 36 . Remarkably, rapamycin a r t I C l e S treatment from P30 to 90 had salutary effects on overall nerve integrity and resulted in dramatic axon protection in PTEN-SCKO mice (Fig. 6a and data not shown). In sharp contrast, the identical treatment regime had no effect on axon integrity in LKB1-SCKO mutants (Fig. 6a,b) .
In addition, we quantified axon numbers in peripheral nerves from SC-specific mTOR mutants (Mtor fl/fl :P0-cre; mTOR-SCKO) and did not observe loss of myelinated or unmyelinated axons during aging, despite substantial myelination deficits and other nerve defects in these mutants (Supplementary Fig. 12 ). Therefore, deregulation of the mTORC1 pathway in SCs does not underlie the axonal phenotype observed in LKB1-SCKO mutants.
The primary metabolic target of LKB1 is AMPK. To determine whether abolition of AMPK activity in SCs could phenocopy the axonopathy in LKB1-SCKO mutants, we generated SC-specific AMPK knockout mice. To ensure complete inactivation of the AMPK complex in SCs, we generated two sets of mutants, with complete ablation in SCs of either all β-subunit isoforms (Prkab1 fl/fl ;Prkab2 −/− :P0-cre, or AMPKβ1/2-SCKO) or all α-subunit isoforms (Prkaa1 −/− ;Prkaa2 fl/fl : P0-cre, or AMPKα1/2-SCKO) (Supplementary Fig. 13a,b) . Contrary to the hypothesis that failure of AMPK activity in SCs may mediate the axonal effects following LKB1 ablation, both AMPKβ1/2-SCKO and AMPKα1/2-SCKO mutants displayed no apparent neurological abnormalities or behavioral defects in a battery of motor and sensory tests from birth to at least 12 months of age ( Supplementary  Fig. 13c,d and data not shown). Nerve morphometry and electron microscopy showed a normal axon structure in these mutant mice (Fig. 6c and data not shown) . The numbers of myelinated and unmyelinated axons in sciatic nerves from AMPKβ1/2-SCKO mice were normal at an early age through 18 months of age, although we did observe progressive hypomyelination (Fig. 6c-e and Supplementary  Fig. 14a ). We obtained similar results from AMPKα1/2-SCKO mice (Supplementary Fig. 14b-d and data not shown) . Hence, while AMPK is often the primary effector of LKB1 metabolic actions, it is not essential to SC-mediated axonal support functions.
LKB1 deletion results in profound metabolic changes
The absence of axonopathy in AMPK-deficient mice prompted us to examine whether AMPK was inactivated in LKB1-SCKO mutants in vivo. Surprisingly, we found increased AMPKα Thr172 phosphorylation (an established indicator for AMPK activation) in P30 LKB1-SCKO nerves (Fig. 7a) . This is consistent with the observed energetic depletion in LKB1-SCKO nerves and suggests that AMPK can be activated via non-LKB1-dependent mechanisms in SCs 11, 37 . Two alternative upstream kinases, the Ca 2+ /calmodulin-activated protein kinase kinase (CaMKK) and the MAP3 kinase Tak1 (MAP3K7, TGF-β-activated kinase-1), can activate AMPK independently of LKB1 in noncanonical pathways [38] [39] [40] . We thus studied their activation levels. We found no changes in CaMKK signaling but a strong activation of Tak1 (phosphorylation at Thr184 and Thr187) in LKB1-SCKO nerves (Supplementary Fig. 15 ), indicating that Tak1 may phosphorylate AMPK in the absence of LKB1.
Activated AMPK is a negative regulator of lipid anabolism via targets such as acetyl-CoA carboxylase (ACC; fatty acid synthesis and oxidation) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR; cholesterol synthesis) 11 . In accord with abnormalities in npg a r t I C l e S lipid metabolism detected in our metabolomics analysis, LKB1-SCKO nerves showed increased phosphorylation of ACC on Ser79 (Fig. 7a) . Correspondingly, we found reduced levels of cholesterol, triglycerides and fatty acids in mutant nerves, although only cholesterol levels showed statistically significant differences at every age studied (Fig. 7b and data not shown). Moreover, in a mass spectrometry-based shotgun lipidomics approach using nerve lipid preparations from P60 mice, we detected reduced levels (by ~35%) of major myelin lipids, including phospholipids (total phosphatidylethanolamine with its subspecies) and glycolipids (total cerebroside with its subspecies) ( Fig. 7c and Supplementary Table 3) . Thus, LKB1 loss unexpectedly leads to induced AMPK activity and to inhibition of SC lipid (especially cholesterol) synthesis before axon loss. AMPK activation also negatively regulates protein synthesis and cell growth through phosphorylation of both TSC2 and Raptor 17, 32 . In addition to slightly increased TSC2 and Raptor phosphorylation, we observed an overall attenuation of the protein synthesis pathway in P30 LKB1-SCKO nerves as reflected by decreased phosphorylation of the mTORC1 downstream targets ribosomal S6 kinase, S6 ribosomal protein and eukaryotic initiation factor 4E-BP1 (Fig. 7a) . The reduced mTORC1 activity is consistent with the reduced nerve and SC size in LKB1-SCKO mice.
LKB1-AMPK signaling controls mitochondrial biogenesis and turnover through regulation of peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α) and UNC-51-like kinases 1 and 2 (ULK1 and ULK2) (ref. 11). Alterations of mitochondrial load and function have been reported following LKB1 elimination 23, 25, 41 . In agreement, LKB1-SCKO nerves showed elevated PGC1α levels with a dramatic increase in the mitochondrial proteins TFAM and VDAC (porin) (Fig. 7d) . Total mitochondrial numbers as well as the cumulative mitochondrial membrane potential were increased in SCs from mutant mice ( Fig. 7e and Supplementary Fig. 16a ). Given the progressive energetic depletion in mutant nerves (Fig. 2a) , this is likely to reflect a compensatory expansion of mitochondria secondary to mitochondrial dysfunction. Consistent with this dysfunction, we observed increased enzymatic cytochrome oxidase (COX) labeling in young LKB1-SCKO nerves, whereas none was noted in aged nerves (Fig. 7f) despite a progressive increase in mitochondrial content (Supplementary Fig. 16b) .
This temporal readout of mitochondrial function in relation to mitochondrial load and increased phosphorylation of the mitophagy regulator ULK1 (Fig. 7d) indicates that mitochondrial homeostasis in LKB1-deficient SCs is abnormal. To further examine whether there are direct detrimental consequences of the mitochondrial dysfunction, we assessed mitochondrial reactive oxygen species (ROS) production in isolated SCs from young and aged mice, as measured by MitoSOX Red biosensor incorporation. We found a slight but significant increase of mitochondrial ROS in LKB1-deficient SCs isolated from 12-month-old mutant nerves as compared to cells from age-matched control mice (Fig. 7g) . Together with the importance of mitochondrial homeostasis in maintenance of nerve integrity, these data suggest the possibility that mitochondrial misregulation in SCs contributes to axonal destabilization in LKB1-SCKO mutants.
On the basis of our metabolomics screen and the importance of lactate in maintaining neuronal compartments in the CNS, we next explored the effects of LKB1 loss on SC glucose regulation. The LKB1-AMPK pathway controls glycolysis via cellular glucose uptake and regulation of glycolytic enzymes 11, 14 . Lactate concentrations were npg a r t I C l e S increased in sciatic nerves of LKB1-SCKO mice starting at P90 (Fig. 8a) , which coincides with the onset of axon degeneration. This was associated with increased lactate dehydrogenase (LDH) enzymatic activity in mutant nerves (Fig. 8b) . Notably, we did not detect significant differences in the expression levels of a number of key glycolytic enzymes or carbohydrate transporters in LKB1-SCKO nerves and LKB1-deficient SCs (Supplementary Fig. 17a-d and data not shown). We also observed no differences in total nerve glucose levels at any age studied (Supplementary Fig. 17e ). To test whether LKB1-deficient SCs release increased amounts of lactate, we cultured control and LKB1-SCKO sciatic nerve explants and measured lactate concentrations in the culture medium after 48 h of incubation. The mutant nerves released significantly higher amounts (P = 0.004) of lactate (6.34 ± 0.23 mM lactate in culture medium; N = 3 mice) than control nerves (4.15 ± 0.28 mM lactate; N = 3 mice), suggesting that peripheral axons in mutant nerves are exposed to increased lactate concentrations.
Increased lactate levels in mutant nerves support axons
The increased lactate release in LKB1-SCKO nerves made us ask whether this is detrimental (by causing tissue acidosis) or beneficial (by providing energy substrate) for axon integrity. At variance with the possibility of adverse lactate effects, incubation of primary dorsal root ganglion axon cultures with increasing concentrations of lactate in the medium did not elicit any apparent axonal degeneration (Supplementary Fig. 18a) . To explore the effects of aberrant nerve lactate levels on axon integrity in vivo, we attempted to reduce lactate production in LKB1-SCKO mutants. P30 mutants were treated for 60 d with 2-deoxy-d-glucose (2DG), a glucose analog that inhibits glycolysis, and the effects on axon survival in sciatic nerves were quantified. The 2DG treatment regime had no appreciable effects on overall behavior or body weight in LKB1-SCKO mice ( Supplementary  Fig. 18b,c) . However, 2DG treatment did normalize nerve lactate levels in LKB1-SCKO nerve preparations by P90, from 5.25 ± 0.19 mM (n = 7, vehicle treated) to 3.64 ± 0.30 mM (n = 11) (P = 0.019), so that no differences in nerve lactate concentration were detectable between treated mutant and control mice (vehicle-treated control, 4.18 ± 0.30 mM (n = 7); 2DG treated control, 3.41 ± 0.50 mM (n = 11)). We found that 2DG administration slightly but significantly exacerbated axon loss in P90 LKB1-SCKO sciatic nerves, whereas it had no effect in control animals ( Fig. 8c,d) . If the increased lactate was toxic to the axons, then lowering lactate with 2DG should have reduced the amount of axonal loss; instead, axon losses increased, suggesting that the increased lactate reflects a compensatory response by the SC and an attempt to provide more support to the deteriorating axons.
DISCUSSION
This study shows that LKB1 is a crucial regulator of major metabolic pathways in SCs that are central to their role in supporting axonal integrity. LKB1-deficient SCs displayed multiple metabolic abnormalities, some of which may reflect alterations in AMPK and mTOR activity. However, the loss of axon maintenance functions in LKB1-deficient SCs was largely independent of AMPK and mTOR signaling. These findings are particularly intriguing in that abnormalities in this pathway have been implicated in metabolic pathologies, aging and neurodegeneration. Furthermore, these studies separate SC axon support functions from their more widely appreciated role in myelination.
In contrast to that in other neuropathy models, the axon degeneration in the LKB1 mutants is not due to demyelination and inflammation. This strongly suggests that axon degeneration is a direct result of perturbed bioenergetics and metabolic support by SCs. Since axon degeneration is a hallmark of many neuropathies, our study opens the possibility that metabolic misregulation in SCs linked to altered LKB1 signaling may be an important contributor to axon loss in these disorders, and especially those associated with aberrant metabolism.
LKB1 deletion in SCs led to energetic depletion, mitochondrial dysfunction and widespread alterations in nerve redox state, lipid metabolism, enzymatic activities and increased lactate. It is likely that many of these alterations reflect contributions from additional AMPK-related kinases (that is, ones other than AMPK) that are also associated with LKB1 metabolic functions 12, 13, 42, 43 . Our finding that complete loss of AMPK activity in SCs is not harmful to axons indicates that abnormal AMPK signaling in SCs is unlikely to be the predominant underlying factor leading to axonal loss, thus implicating glial AMPK-related kinases or other LKB1 targets in axon maintenance. Suppression of mTOR signaling likewise does not result in axonal degeneration, as aged SC-specific mTOR mutants had normal axon numbers and rapamycin administration in LKB1-SCKO mutants had no effect on axon stability. These data indicate that metabolic changes in LKB1-deficient SCs, which are largely independent of AMPK and mTOR, must be responsible for the axon degeneration in these mice. Indeed, these SC axonal support modalities are needed continually for proper axon maintenance, as inducible deletion of LKB1 in SCs in adult mice led to a dramatic axonal loss. We thus propose that LKB1, together with specific downstream substrates, provides the appropriate balance npg a r t I C l e S of metabolic pathways that ultimately leads to long-term support of axon integrity. Future studies will have to elucidate which pathways downstream of LKB1 and its substrates are important here. Each of the characterized metabolic changes in mutant SCs, separately or in combination, may contribute to axonal loss. Because glial lactate provides support for CNS axons 4,5 , we sought to determine the role of elevated lactate in LKB1-depleted nerves. We found that abolishing the increased lactate production from these mutant SCs resulted in further axon pathology. This demonstrates that glial release of lactate also supports axon integrity in the PNS and extends this function to pathological situations where it appears to be a compensatory response aimed at sustaining distressed axons. Notably, increased nerve lactate also has been observed in rodent models of diabetic neuropathy 44, 45 . Thus, it will be interesting to also explore the effect of lactate on axon integrity in these models.
Despite LKB1 elimination, mutant SCs in vivo appear to respond with robust activation of AMPK. This surprising effect has also been observed in other LKB1-deficient cells 18, 38 , but remains poorly understood. The strong activation of Tak1 signaling in LKB1-SCKO nerves suggests that Tak1 acts as an upstream kinase for AMPK 39, 40 in SCs under stress conditions. How Tak1 is activated in LKB1-deficient cells is unclear, but it may involve sensing the energetic deficits in these cells. In LKB1-SCKO nerves, some of the compensatory effects, such as increased lactate release through enhanced glycolysis, are possibly the direct consequence of AMPK activation in LKB1-SCKO nerves.
Despite the axon demise in tamoxifen-inducible LKB1-iSCKO mice, there were no changes in myelination in these mutants except the focal myelin breakdown as a direct consequence of axon degeneration. This suggests that LKB1 in adult SCs is dispensable for the maintenance of compact myelin once it is formed, which is consistent with the lack of demyelination in the LKB1-SCKO mutants (although LKB1-SCKO mutants did show delayed SC maturation and developmental myelination, likely as a result of the metabolic dysregulation). The exclusion of demyelination as etiological factor for the axonopathy in LKB1-SCKO mice is perhaps surprising given the alterations in lipid metabolism and aberrant mitochondrial homeostasis. Recently, we mechanistically linked a demyelinating neuropathy resulting from SC mitochondrial dysfunction, in the Tfam fl/fl :P0-cre (Tfam-SCKO) mutant, to aberrant lipid metabolism and to activation of the integrated stress response 6 . In particular, we proposed that reduction of myelin-enriched lipids (sulfatides and cerebrosides) and accumulation of detrimental acylcarnitine species in Tfam-SCKO nerves contribute to nerve demyelination with subsequent axon loss. Our lipidomics screen revealed normal levels of acylcarnitines in LKB1-SCKO nerves (Supplementary Table 3) , excluding a similar lipotoxic mechanism. Instead, it is possible that the low levels of various myelin lipids in LKB1-SCKO nerves are secondary to attenuation of energy-costly lipid synthesis as a result of increased AMPK activity. In agreement, our microarray analysis revealed early and significant downregulation of squalene epoxidase, a central and rate-limiting step in cholesterol 46 and thus myelin synthesis.
The preferential degeneration of small-diameter unmyelinated afferents in LKB1-SCKO mutants and relative sparing of large-caliber motor axons calls for a comparison to acquired human neuropathies, especially those associated with diabetes, obesity and aging. The most common and incapacitating symptoms in these conditions (namely, pain and paresthesias) are those associated with small-fiber degeneration, whereas large motor fibers are relatively spared. The underlying mechanisms accounting for the high vulnerability of small-diameter axons in these conditions are unexplained. Although various hypotheses have been proposed [47] [48] [49] , the potential contribution of SC abnormalities to this vulnerability has not been appreciated. Furthermore, LKB1-SCKO mice also manifest extensive axon degeneration in the vagus nerve, which contains mostly small parasympathetic fibers, mimicking an important feature of autonomic diabetic neuropathy 50 . Although diabetic polyneuropathy is certainly a multifactorial disorder, our discovery that metabolic dysregulation in SCs triggers primarily small-fiber degeneration may help to limit the number of potential underlying mechanisms and put new emphasis on the SC as a pathophysiologic target. This selective loss could reflect a greater dependence of small unmyelinated axons on SC bioenergetic support 3 . Alternatively, it is conceivable that their instability arises from accumulation of harmful metabolites, which would lead to much higher concentrations in small axons owing to their lower axoplasm volume. The discrimination among such mechanistic scenarios will require future work and will need to incorporate measurements of metabolic and other changes in the axon directly through metabolic sensors and other modalities.
METhODS
Methods and any associated references are available in the online version of the paper.
Accession codes. GEO: GSE60325.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METhODS generation of Sc-specific mutant mice. All animal experiments were reviewed and approved by the Washington University Animal Studies Committee (protocol approvals 20110071 and 20140044). LKB1-SCKO mutants and control littermates were generated by crossing Lkb1 fl/fl mice 51 (FVB) to P0-cre transgenic mice 52 (C57BL/6). LKB1-SCKO mutants were also crossed to Thy1.2-YFP-16 mice 53 and Plp-EGFP transgenic mice 54 (both C57BL/6) for fluorescent axon and SC imaging, respectively. For SC-specific LKB1 ablation in adult animals (LKB1-iSCKO), Lkb1 fl/fl mice were crossed to Plp-cre ERT transgenic mice 55 (C57BL/6).
The following mutant mouse strains were obtained from the European Conditional Mouse Mutagenesis program (EUCOMM) and Knockout Mouse Project (KOMP) (Wellcome Trust Sanger Institute, Mouse Genetics Programme): B6N-Mtor tm1a(EUCOMM)Wtsi (for mTOR deletion); B6N-Prkab1 tm1a(KOMP)Wtsi (for AMPKβ1 deletion) (both C57BL/6). Mtor fl/fl and Prkab1 fl/fl mice were generated by crossing these mutant mouse strains to germ cell-expressing Flp recombinase transgenic mice 56 (C57BL/6) to deactivate the 'knockout-first allele' promoterless cassette (containing splice acceptor, lacZ, neo and polyadenylation signal for constitutive knockout).
mTOR-SCKO mutants were generated by crossing Mtor fl/fl mice to P0-cre transgenic mice. For generation of AMPKβ1/2-SCKO mutants, Prkab1 fl/fl mice were crossed to Bay Genomics gene-trap AMPKβ2-deficient (Prkab2) mutants 57 (C57BL/6) and P0-cre transgenic mice. For generation of AMPKα1/2-SCKO mutants, AMPKα2 fl/fl (Prkaa2 fl/fl ) mice 58 (C57BL/6) were crossed to AMPKα1 (Prkaa1) mutants 59 (C57BL/6) and P0-cre transgenic mice. PTEN-SCKO mutants were generated by crossing Pten fl/fl mice 60 (C57BL/6) to P0-cre transgenic mice. Genotyping for all mutants was performed by PCR strategies using standard procedures and appropriate primers (sequences available upon request).
Tamoxifen, rapamycin and 2dg treatment of mice. Intraperitoneal injections of tamoxifen (Sigma; daily 180 µg per gram mouse weight) and rapamycin (LC Laboratories, daily 10 µg per gram mouse weight) were performed similarly to previously reported procedures 36, 61 .
2-Deoxy-d-glucose (2DG) (Sigma) was dissolved in physiological saline to a final concentration of 40 mg/ml. P30 mice received daily intraperitoneal injections (Monday-Saturday) at 500 µg 2DG per gram mouse weight or received only the carrier solution as a control.
Histology of nerves and muscles. Processing of samples for generation of semithin and ultrathin nerve sections was performed as described previously 62, 63 . Hematoxylin and eosin staining of mouse muscle sections was performed using standard procedures. Preparation and imaging of tibial nerve teased fibers from mice expressing the Plp-EGFP transgene was performed as reported previously 63 .
confocal imaging of YFP-or egFP-labeled whole-mount nerve and muscle preparations and skin intraepidermal fibers. For analysis of YFP-labeled axons or EGFP-labeled SCs in whole-mount nerve preparations from mice expressing the Thy1.2-YFP-16 or Plp-EGFP transgenes, ~1.5-cm-long sciatic nerve segments were dissected, processed and imaged as previously described 64 .
Neuromuscular junctions (NMJs) and intramuscular nerve fibers in fixed flexor digitorum brevis, extensor halluces longus and lumbrical muscles from mice expressing the Thy1.2-YFP-16 transgene were visualized by staining of acetylcholine receptors with tetramethylrhodamine isothiocyanate conjugates of α-bungarotoxin (TRITC-α-BTX; Biotium). Muscle preparations were mounted on glass slides in Vectashield mounting medium for subsequent confocal or widefield epifluorescence imaging. Total numbers of intact NMJs were counted in whole-mount preparations of extensor halluces longus muscles applying previously reported criteria 62 . NMJs in both limb muscles of each experimental animal were quantified.
For imaging of intraepidermal axon terminals in mice expressing Thy1.2-YFP-16, skin biopsies were collected from hind paws, immersion-fixed in Zamboni fixative and embedded in OCT medium for production of frozen sections. Confocal imaging was used for visualization of YFP-labeled intraepidermal axon terminals.
Quantification of myelinated and unmyelinated axons in peripheral nerves.
We performed counts of intact axons in sciatic, quadriceps, saphenous and sural nerves as well as ventral and dorsal spinal cord roots on high-magnification semithin micrographs using established unbiased counting methods 62, 64, 65 . The ImageJ software cell-counter plug-in and calibrated area measurements were used for axon quantification. For manual quantification of myelinated fiber numbers in sciatic nerves, we counted axons in at least four randomly selected images of the sciatic nerve transverse section, each 6,000 µm 2 . Total numbers of axons in the whole nerve were extrapolated on the basis of the total area of the nerve. For facilitated quantification of unmyelinated axons in Remak bundles in sciatic nerves, we calculated the area occupied by preserved unmyelinated axon bundles in at least four randomly selected images of the sciatic nerve section, each 6,000 µm 2 . The total area of unmyelinated axon bundles in each transverse nerve sections was calculated by interpolation. For quantification of myelinated fibers in quadriceps, saphenous and sural nerves as well as ventral and dorsal spinal cord roots, all axons on each transverse section were counted. Counts were carried out by B.B. or E.B. on samples whose identity was masked.
calculation of g-ratios and quantitative histomorphometry. g-ratios of individual myelinated axons in sciatic nerves as a measure of myelin thickness were determined using a plug-in for the ImageJ software that allows semiautomated analysis of randomly selected axons on nerve transverse sections (http://gratio.efil.de/). Using four randomly selected semithin light micrographs (each 6,000 µm 2 ) per sciatic nerve section from each analyzed mouse, we performed measurements on a total of 100 randomly chosen fibers. Cumulative g-ratios were calculated for each mouse by averaging all individual g-ratios.
Fiber size distribution morphometry was carried out using an automated digital imaging system and custom-made morphometry software (Leco IA32, Leco Instruments) as described previously 63, 66 .
Immunofluorescence and cell quantifications. Dissected sciatic nerves were immersion-fixed in 4% PFA in PBS for 1-24 h, cryoprotected in 30% sucrose and embedded in Tissue-Tek OCT compound (Sakura Finetek). Immunofluorescence on longitudinal and transverse frozen nerve sections, including TUNEL staining, was performed as described previously 28, 63 . DAPI-positive SC nuclei and TUNEL-, Iba1-, CD68-and CD3-positive cells were quantified on entire transverse sciatic nerve sections. Counts were carried out by B.B. on samples whose identity was masked.
nerve cytochrome oxidase staining. Sciatic nerves from control and LKB1-SCKO mutant mice were freshly dissected, placed in Tissue-Tek OCT compound and immediately frozen. An incubating solution containing 75 mg/ml sucrose, 0.5 mg/ml 3,3′-diaminobenzidine tetrahydrochloride 2 (DAB, 0.6 mg/ml), 2 µg/ml catalase (from bovine liver) and 1 mg/ml cytochrome c in 0.05 M sodium phosphate was placed on longitudinal cryosections (12 µm) for 60 min at room temperature. The sections were then washed three times with deionized water, dehydrated in a series of ascending alcohols, cleared with xylene and mounted using Permount (Fisher).
Fluorescence in situ hybridization. Fluorescence in situ hybridization on sciatic nerve sections was performed using the QuantiGene ViewRNA Tissue 2-Plex Assay kit (Affymetrix) according to the manufacturer's instructions. For detection of Lkb1 transcripts, a type 1 probe set was designed by Affymetrix corresponding to the bases 304-1368 of NM_011492. For detection of myelin basic protein (Mbp) transcripts, a type 6 probe set was designed corresponding to the bases 17-2045 of NM_010777.
Quantification of dorsal root ganglion neurons. Expression of the Thy1.2-YFP-16
transgene results in YFP-labeling of all mouse dorsal root ganglion (DRG) neurons 53 , allowing accurate quantification of neuronal cell body numbers. Entire DRGs (L1-L5) were dissected from control Lkb1 fl/fl (Thy1.2-YFP-16) and mutant Lkb1 fl/fl :P0-cre + (Thy1.2-YFP-16) mice, cleaned of connective tissue and mounted on glass slides. Neuronal cell body numbers per DRG were determined, on samples whose identity was masked, using the ImageJ software cell-counter plug-in and manual counting. microscopic nerve imaging. We used a Nikon Eclipse 80i or Nikon Eclipse TE300 microscope system coupled to a digital camera (CoolSnapES2; Photometrics) for presentation of images from frozen and plastic semithin sections, or npg phase-contrast images from neuronal culture experiments. Confocal imaging was performed using a Zeiss LSM5 Pascal confocal system and Zeiss Confocal Software. Electron micrographs of ultrathin sections were taken with Hitachi H-7500 or JEOL TEM 1200 EX II transmission electron microscopes.
Quantitative real-time PcR. Nerve RNA was extracted using the Zymo Research DNA-Free RNA Kit according to the manufacturer's recommendations. The nerve RNA was treated with DNase (RQ1 Promega), and a noreverse-transcriptase control ensured absence of genomic DNA contamination. qRT-PCR for quantification of gene transcripts in sciatic nerves was performed as described previously 63 using a SYBR green-based assay on an ABI 7900 HT sequence detection system (Applied Biosciences). For each individual transcript, expression data from at least three Lkb1 fl/fl control and three age-matched LKB1-SCKO mutant mice was obtained and normalized to glyceraldehyde-3-phosphate dehydrogenase (Gapdh) expression. Primers were as follows: Gapdh forward: TGCCCCCATGTTTGTGATG; Gapdh reverse: TGTGGTCATGAGCCCTTCC; Lkb1 forward: GGGTCACACTTTACAACATCAC; Lkb1 reverse: CGGCTCAT ACTCCAACATCC; Glut1 (Slc2a1) forward: GCTGTGCTTATGGGCTTCTC; Glut1 reverse: CACATACATGGGCACAAAGC; Glut3 (Slc2a3) forward: AT GGGGACAACGAAGGTGAC; Glut3 reverse: GTCTCAGGTGCATTGATG ACTC; Glut4 (Slc2a4) forward: ACATACCTGACAGGGCAAGG; Glut4 reverse: CGCCCTTAGTTGGTCAGAAG. Mct1 (Slc16a1) forward: ATCGCA GGTGGCATTTTAAG; Mct1 (Slc16a1) reverse: GTCACGCATACTCCGGGC; Mct2 (Slc16a7) forward: GCTCTATCACGCTGTTGCTG; Mct2 reverse: GCTAGCTGTCATGTATGCGG; Mct4 (Slc16a3) forward: TCACGGGTTT CTCCTACGC; Mct4 reverse: GCCAAAGCGGTTCACACAC. Quantification of mitochondrial DNA content in sciatic nerves was performed as described previously 28 .
microarray and computational analysis. Sciatic nerves from P60 Lkb1 fl/fl control (N = 6 mice) and LKB1-SCKO mutant mice (N = 6 mice) were dissected, cleaned of surrounding fat and connective tissue, and rapidly frozen in liquid nitrogen. Nerve RNA was extracted using a Qiagen mRNeasy Mini Kit according to the manufacturer's recommendations. Subsequent microarray analysis of nerve RNA using Illumina Mouse WG-6 v2.0 Expression Bead-chips was performed as described previously 6 . Probes having detection P values >0.05 in all samples were removed and a two-class unpaired SAM analysis was performed. Differentially expressed genes with at least 2.0 fold differential regulation between control and LKB1-SCKO samples at a false discovery rate (FDR) of 2.5% were selected for analysis (presented in Supplementary Table 2 ). The Gene Expression Omnibus (GEO) accession number for the microarray data reported in this paper is GSE60325. measurement of metabolites in peripheral nerves and in cell culture medium. For all metabolite measurements, sciatic nerves from Lkb1 fl/fl control and agematched LKB1-SCKO mutant mice were processed in parallel. For quantification of ATP, ADP and NAD + , sciatic nerves were rapidly dissected, weighed, immediately placed in 10 volumes ice-cold perchloric acid (HClO 4 ) and homogenized by sonication for 5 s. After tissue pH neutralization (K 2 CO 3 ) and centrifugation steps, the extracts were analyzed using a Shimadzu high performance liquid chromatography (HPLC) system equipped with a LC-18T reverse-phase column (Supelco) and quantification software (LabSolutions) as described previously 6 . The nucleotide concentrations were determined by measuring the absorbance at 254 nm and comparing to standards.
For quantification of sciatic nerve NAD + /NADH ratios, weighed nerves from each mouse were divided for extract preparations in HClO 4 (for NAD + measurement) and K 2 CO 3 solutions (for NADH measurement) in parallel. After homogenization and centrifugation, nerve extracts were kept at 55 °C for 15 min, incubated on ice, and pH neutralized. NAD + /NADH ratios in these extracts were determined using a fluorometric assay kit (BD Bioquest Enzo Works Fluorimetric NAD/NADH assay kit; red fluorescence) and a BMG Labtech Polarstar Optima fluorescence plate reader with attached analysis software.
For measurements of nerve glucose and lactate concentrations, sciatic nerves were rapidly dissected, weighed and placed in 10 volumes ice-cold artificial cerebrospinal fluid. Following homogenization and centrifugation, glucose and lactate concentrations in nerve extracts were measured using a YSI Life Sciences 2700 Select Biochemistry Analyzer equipped with d-glucose and l-lactate detection sensors.
Total cholesterol, triglyceride and fatty acid levels in sciatic nerves were determined using colorimetric assays with commercial detection reagents (Infinity Total Cholesterol and Infinity Triglycerides, Thermo Scientific; NEFA HR(2), Wako Chemicals). Snap-frozen sciatic nerves were weighed, homogenized in chloroform:methanol (2:1) and centrifuged at ~11,000g for 10 min at 4 °C. Aliquots for the respective measurements were evaporated in a microcentrifuge tube, and the detection reagents were added and incubated at room temperature. The solutions were transferred to a 96-well plate with standards for cholesterol, triglyceride and fatty acids, and the respective concentrations were determined with a plate reader following the manufacturer's instructions. measurement of lactate dehydrogenase enzyme activity in nerves. LDH enzyme activity in sciatic nerve homogenates was determined using the Lactate Dehydrogenase Activity Assay kit (Sigma) according to the manufacturer's instructions. In this assay, LDH reduces NAD + to NADH, which was specifically detected by a kinetic colorimetric measurement algorithm using a BMG Labtech Polarstar Optima plate reader and attached analysis software. Sciatic nerves were rapidly dissected from Lkb1 fl/fl control and age-matched LKB1-SCKO mutant mice (at least three per genotype), weighed and immediately placed in ice-cold LDH assay buffer. Nerves were homogenized by sonication for 10 s and centrifuged, and an aliquot of the supernatant was used for the subsequent colorimetric measurement to determine LDH activity in milliunits/ml. nerve protein analysis and western blotting. Western blotting was performed using standard procedures as described previously 62, 63 . Integrated intensities of protein bands were measured using the ImageJ densitometry plug-in and normalized by comparison with the loading control (β-actin).
Tissue metabolite extraction for untargeted metabolomics. Sciatic nerves from P60 Lkb1 fl/fl control (N = 11 mice) and LKB1-SCKO mutant mice (N = 11 mice) were dissected, cleaned of surrounding fat and connective tissue, and rapidly frozen in liquid nitrogen. Nerve tissues were lyophilized and normalized by mass before being extracted as previously described 67 . Lyophilized tissues were first treated with 600 µl of cold acetone, vortexed for 30 s, incubated in liquid nitrogen for 1 min and then sonicated for 10 min after being thawed at room temperature. This procedure was repeated three times. After a 1-h incubation at −20 °C, samples were centrifuged for 10 min at ~13,000g and 4 °C. The resultant supernatant was transferred to a separate vial and kept at −20 °C. The remaining pellet was then treated with 400 µl of cold methanol/ water/formic acid (86.5:12.5:1.0). After vortexing for 30 s and sonicating for 15 min, the samples were stored at −20 °C for 1 h. Samples were then centrifuged at ~13,000g for 10 min and the supernatant was collected. The supernatant was then pooled with that from the first extraction and dried by using a vacuum concentrator. After drying, each sample was either reconstituted in 100 µl of acetonitrile/water (95:5) for nonpolar metabolites or in 100 µl of methanol for polar metabolites. metabolomics liquid chromatography/mass spectrometry analysis and data processing with XcmS software. Each extracted sample was injected onto an HPLC column coupled to an Agilent 1200 series HPLC system. Two HPLC columns, a reversed-phase C18 (RP-C18) column (Agilent ZORBAX SB-C18 column, 150 mm × 0.5 mm) and an aminopropyl column (Phenomenex, 150 mm × 1.0 mm) were used to separate nonpolar and polar metabolites, respectively. The solvent system for RP liquid chromatography was water with 0.1% formic acid (mobile phase A) and acetonitrile with 0.1% formic acid (mobile phase B). The solvent gradient started with 2% B from 0 to 10 min and proceeded to 10% B from 10-15 min, 20% B from 15-50 min, 95% B from 50-60 min and 98% B by the end.
The aminopropyl column was used in hydrophilic interaction (HILIC) mode with the following buffers: A = 95% water, 5% acetonitrile, 10 mM ammonium hydroxide, 10 mM ammonium acetate, pH 9.45; B = 95% acetonitrile, 5% water. The separations were done by using the following gradient: 100% B from 0 to 5 min, 100% to 0% B from 5 to 50 min, 0% B from 50 to 55 min. MS analysis was carried out on an Agilent 6520 Q-TOF with an electrospray ionization source in both positive and negative mode. All MS1 spectra were collected with an acquisition rate of 1.02 spectra/s with a mass range of 30-1,500 mass units. The raw data npg files were converted into mzXML files using msconvert. The metabolite profiling analysis was performed on XCMS Online by using the centWave algorithm for features detection with peakwidth = 10-120 s and ppm = 20. nerve lipidomics. Sciatic nerves from P60 Lkb1 fl/fl control (N = 3) and LKB1-SCKO mutant mice (N = 3) were dissected, cleaned of surrounding fat and connective tissue, and rapidly frozen in liquid nitrogen. Nerve sample lipid extract preparations for mass spectrometry and subsequent analyses of lipid extracts by multidimensional mass spectrometry-based shotgun lipidomics were performed as described previously 6,68 .
Schwann cell culture. Mouse sciatic nerves were rapidly dissected and placed in a sterile dish containing ice-cold DMEM. The nerve segments were freed of fat and connective tissue and coarsely teased into smaller fascicles using fine forceps. For dissociation of SCs, the nerve tissue was treated with two sequential 15 min incubations at 37 °C using first a solution consisting of Liberase TM 7 µg/ml, BSA 0.01 mg/ml, DNase I 0.6 mg/ml and then trypsin 0.05%, and was then triturated gently with a P1000 pipetter. After centrifugation at 800g for 5 min, the final dissociated material was suspended in SC medium (DMEM, bovine pituitary extract 2 µg/ml, forskolin 2 µM, FBS 10%, penicillin/streptomycin) and seeded on polycarbonate FluoroDish cell culture dishes previously coated with poly-d-lysine (0.1 mg/ml) and laminin (0.01 mg/ml). Degenerating axon portions and dead cells were washed out by frequent medium washes. Ara-C (10 nM) was applied at DIV 2-3 to limit the growth of fibroblasts. The presence of EGFP fluorescence from the Plp-EGFP allele or immunolabeling with S100 confirmed the presence of SCs at DIV 5-6.
live imaging of Schwann cell mitochondria. For imaging of SC mitochondria and their mitochondrial membrane potential or mitochondrial reactive oxygen species, primary SC cultures were loaded with following indicator dyes (all Invitrogen) at DIV 5-6: MitoTracker Red CMXRos (250 nM, 10 min incubation); TMRM (tetramethylrhodamine methyl ester; 50 nm, 30 min incubation); MitoSOX Red (5 µM, 10 min incubation). After incubation, the cultures were washed with fresh medium and transferred into a live-imaging environmental chamber (5% CO 2 , 37 °C) mounted on a Quorum spinning disc confocal/ IX81-Olympus inverted microscope. Picture acquisition was performed using a 40× objective and MetaMorph software. The mitochondrial indicator labeling was validated by addition of the mitochondrial uncoupler CCCP to the culture medium. Fluorescence intensity in individual SCs was assessed using ImageJ as described previously 62 . Briefly, after confirmation of EGFP fluorescence (from the Plp-EGFP allele), the area in each confocal micrograph occupied by SCs was defined using the ImageJ 'threshold' function, and the average red fluorescence intensity derived from the indicator dyes (MitoTracker RedCMXRos, TMRM, MitoSOX Red) was measured within this SC area. For each dye, SC cultures from sciatic nerves from three mice per genotype and examined age were used in three separate experiments. For each experiment, we assessed fluorescence intensity in ten microscopic fields with ~40 cells. For high-resolution analysis of mitochondrial number and shape in individual SCs, Mitotracker Red CMXRos was also imaged after fixation with 4% PFA in PBS using a Nikon D-Eclipse C1 confocal microscope. lactate treatment of dorsal root ganglion cultures. DRGs were dissected from E13.5 CD1 embryos and cultured as described previously 69 . DRG culture medium containing lactate (Sigma) at the indicated concentrations was applied starting from DIV 5 and changed every 24 h to ensure constant levels for the following 8 d.
nerve explant culture for measurement of lactate in culture medium. Using sterile conditions, sciatic nerves (~5 mm) were removed quickly from P60 Lkb1 fl/fl control (N = 3) and LKB1-SCKO mutant mice (N = 3) that had been humanely killed. The nerve segments were transferred to ice-cold DMEM in a sterile dish. After removal of the perineurium, the nerves were cut into smaller segments, mechanically dissociated with a fine forceps and transferred into a sterile fourwell dish containing 250 µl Neurobasal medium (Gibco) supplemented with Fungizone. These preparations were then cultured in a humidified atmosphere at 37 °C, 5% CO 2 . The conditioned medium was collected after 48 h for quantification of lactate concentrations. nerve electrophysiology. Measurements of nerve conduction velocities and amplitudes of compound muscle action potentials (CMAPs) were performed as described previously 63 .
Behavioral testing. Behavioral testing was performed using male and female SC-specific mutants and control littermates, or age-matched control animals with the appropriate genotypes. The experimenter was blind to the genotypes of the mice during data acquisition. Rotarod, hanging wire, and pole climb and turn tests were performed as previously described with minor modifications 63, 70 . Standardized grip strength analysis of mouse anterior limbs was performed on a TSE Systems grip-strength meter (#303500) according to the manufacturer's instructions. Data are displayed as grip strength in ponds divided by the body weight of the experimental animal in kilograms.
Sensory analyses including Hargreaves, von Frey and acetone tests were performed as described previously 28, 63, 70 . Exclusively female mice were used for these sensory tests. For the hot-and cold-plate tests, female and male mice were placed on a hot-or cold-plate analgesia meter (Ugo Basile) set to 55 °C or 3 °C, respectively. The time it took the animals to start licking their forelimbs or to jump was recorded (time to pain reaction).
Antibodies. The primary and secondary antibodies used for nerve immunostaining and western blotting according to the manufacturer's recommendations are listed in Supplementary Table 4 .
Statistical analysis and presentation of data. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported in previous publications 6, 28, 63 . Data for all experiments were collected and processed randomly, but no formal randomization was carried out for this study. All photomicrographs shown (immunolabeling, light and electron microscopy) are representative of at least three biological replicates. All quantitative data are presented as mean (± s.e.m.) except in box-and-whisker plots (maximum, 25th percentile, median, 75th percentile, minimum). All statistical analyses were performed using GraphPad Prism software (v6). A two-tailed Student's t-test was used for group comparisons, which were considered statistical significant if P < 0.05.
A Supplementary methods checklist is available.
